[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AlertsAndNews Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::818548189724807168.png) AlertsAndNews [@AlertsAndNews](/creator/twitter/AlertsAndNews) on x 5234 followers
Created: 2025-07-18 02:51:08 UTC

$MESO PR here

Mesoblast Reports $13.2M in Q2 Ryoncil® Launch Revenue, $1.6M in TEMCELL® Royalties

Mesoblast posted $13.2M in unaudited Q2 revenue from Ryoncil® sales following its March XX U.S. launch. Ryoncil is the first FDA-approved MSC therapy for pediatric SR-aGvHD. The company also reported $1.6M in royalties from Japan sales of TEMCELL®, and ended the quarter with $162M in cash. Net operating cash burn was $16.6M.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946040007593976075/c:line.svg)

**Related Topics**
[$162m](/topic/$162m)
[japan](/topic/japan)
[$16m](/topic/$16m)
[$132m](/topic/$132m)
[$meso](/topic/$meso)

[Post Link](https://x.com/AlertsAndNews/status/1946040007593976075)